The one randomised trial that combined an incretin with supervised exercise
The older-adult diet-and-exercise trials are the closest analogue to rapid pharmacological weight loss, and they are twenty years old.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 6 of 25 of this archive, newest first.
The older-adult diet-and-exercise trials are the closest analogue to rapid pharmacological weight loss, and they are twenty years old.
The evidence base is thin and the document says so, which is to its credit.
Mass and function are different endpoints and training affects them differently. Most coverage treats them as one.
The evidence base is thin and the document says so, which is to its credit.
The evidence base is thin and the document says so, which is to its credit.
The four-week step exists because four to five weeks is approximately how long a once-weekly drug takes to stop rising at a fixed dose. That is a good reason, and it is not…
The arithmetic of the reference change value, worked for the analytes that matter here.
We work the arithmetic out in full, because it is arithmetic and it is short.
The evidence base is thin and the document says so, which is to its credit.
The evidence base is thin and the document says so, which is to its credit.
What the trials measured, which in the case of micronutrients is very little.
The evidence base is thin and the document says so, which is to its credit.
The evidence base is thin and the document says so, which is to its credit.
A substantial proportion of the abnormal results generated during rapid weight loss are consequences of the weight loss rather than findings about the person.
Why the reason for stopping changes what happens afterwards.
The evidence base is thin and the document says so, which is to its credit.
The evidence base is thin and the document says so, which is to its credit.
Two withdrawal-design trials tell us what happens when treatment stops. Neither tells us what the lowest effective maintenance dose is.
A needle blunts on first use. Reuse is uncomfortable, and it is a documented contributor to lipohypertrophy.
The evidence base is thin and the document says so, which is to its credit.